Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:07:39 EST Sat 07 Mar 2026
Enter Symbol
or Name
USA
CA



Q:FDMT - 4D MOLECULAR THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FDMT - Q0.17.00·10.090.18.48-0.16-1.9516.94,0615,6748.40  8.68  8.1912.34  2.23519:23:43Feb 1915 min RT 2¢

Recent Trades - Last 10 of 5674
Time ETExPriceChangeVolume
19:23:43Q8.49-0.15100
19:22:13Q8.49-0.15100
19:21:50Q8.49-0.15100
19:21:38Q8.49-0.15100
19:21:24Q8.49-0.15100
19:21:09Q8.49-0.15100
19:20:58Q8.49-0.15100
19:20:49Q8.49-0.15100
19:20:26Q8.49-0.15100
19:20:10Q8.49-0.15100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-19 08:00U:FDMTNews Release4DMT to Participate in Upcoming Investor Conferences
2026-02-13 16:05U:FDMTNews Release4DMT Announces New Employment Inducement Grants
2026-02-09 08:00U:FDMTNews Release4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
2026-01-17 08:01U:FDMTNews Release4DMT Announces New Employment Inducement Grants
2026-01-07 08:00U:FDMTNews Release4DMT Provides Company Update and Anticipated Development Milestones for 2026
2025-12-17 07:00U:FDMTNews Release4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
2025-12-12 16:05U:FDMTNews Release4DMT Announces New Employment Inducement Grants
2025-12-08 08:00U:FDMTNews Release4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-11-20 20:00U:FDMTNews ReleaseNovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
2025-11-20 08:00U:FDMTNews Release4DMT to Participate in 8th Annual Evercore Healthcare Conference
2025-11-17 06:00U:FDMTNews Release4DMT Appoints Kristian Humer as Chief Financial Officer
2025-11-14 16:05U:FDMTNews Release4DMT Announces New Employment Inducement Grants
2025-11-10 08:00U:FDMTNews Release4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
2025-11-06 16:05U:FDMTNews Release4DMT to Participate in Jefferies 2025 London Healthcare Conference
2025-11-06 06:24U:FDMTNews Release4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
2025-11-06 06:00U:FDMTNews Release4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years
2025-10-30 23:02U:FDMTNews Release4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
2025-10-17 16:05U:FDMTNews Release4DMT Announces New Employment Inducement Grants
2025-10-14 08:01U:FDMTNews Release4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
2025-10-13 08:00U:FDMTNews Release4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation